A tidal wave of pills: Notre Dame economists help determine how to remediate the opioid crisis
Paul Farrell Jr. was enjoying his extended family’s Sunday ritual of an after-Mass meal at his parents’ house in Huntington, West Virginia, when the challenge that would transform his life and reverberate across the country landed on the breakfast table.
His father was wearing an apron and cooking bacon. His mother dropped onto the table a newspaper story—which would later win a 2017 Pulitzer Prize for Eric Eyre of the Charleston Gazette-Mail—that first made the country aware of an opioid crisis in which nearly 800 million pills were dumped into a state of 1.8 million people.
“We saw it here first—we call it ground zero for a reason,” Farrell said. “It’s claimed the lives of my friends and my friends’ children, my neighbors. You will not find anybody in this community that has not been impacted. We have an epidemic of grandparents raising grandchildren because of a lost generation.”
“This wasn’t a wave, this was a tidal wave of pills into communities.”–Paul Farrell, Jr.
Farrell’s mother wanted to know what he was going to do about it. He pleaded that he was a personal injury lawyer, but she knew he would fight for his hometown. So Farrell, a political science major who graduated from Notre Dame in 1994, combed through his law books until he found a statute—chapter 7-1-3kk—that jumped off the page, giving the county commission the power to eliminate and abate a public nuisance.
“The opioid litigation didn’t start with a lawsuit; it started with an idea,” Farrell said. “If the Exxon Valdez crashed into our shores and spilled oil all over, we would have the power to force Exxon to clean up the oil spill. Well, somebody crashed into our shore and dumped 80 million pills into Huntington, West Virginia. They broke it. Now they need to fix it.”
Farrell went back to his Notre Dame roots for guidance. He asked economist Bill Evans, a co-founder of the Wilson Sheehan Lab for Economic Opportunities (LEO), to curate the data that tracks every pill from manufacturer to distributor to pharmacy for future academic research to study how opioids overwhelmed the health care system—and how to stop it from happening again.
Originally published by al.nd.edu on August 05, 2024.
atLatest Research
- Notre Dame’s Meenal Datta launches cancer research — and students’ careers — through space industry partnershipsWith its first voyage, planned for later this year, the Dream Chaser will make history as the only commercial runway capable spaceplane. The launch will also be a momentous occasion for University of Notre Dame researcher Meenal Datta.…
- Notre Dame and Caltech upgrade world-class spectrograph that powers astronomical discoveryBased at the summit of Hawaii’s Mauna Kea, the W. M. Keck Observatory…
- Notre Dame researchers pioneer the use of “bridge” nanoparticles to fight esophageal cancerThe gold-dotted silica nanoparticles…
- College of Science Announces 2024-25 Faculty AwardsSantiago Schnell, D.Phil., the William K. Warren Foundation Dean of the College of Science, has announced several faculty awards for the 2024–2025 academic year. Father James L. Shilts, C.S.C./Doris and Gene Leonard Teaching Award This award, bestowed annually on a faculty…
- Innovation and dignity: Keough School graduate leverages digital technologies to make a differenceFatima Faisal Khan, a 2024 graduate of the Keough School’s Master of Global Affairs program, works as an associate for ecosystem trust and safety at the Institute for Security and Technology, a think tank that provides impactful solutions to pressing technological issues. In this conversation, she shares how her experience and education at the Keough School prepared her to make a difference in her current role.
- Fighting drug resistance in cancer and bacteriaDrug resistant bacteria is something that is of grave cause of concern for scientists. The fear is that without the development of new antibiotics that work different from what we already have, we could face infections that are resistant to all existing treatments. Similarly, drug resistance in cancer…